Cargando…
Dasatinib Targets B-Lineage Cells but Does Not Provide an Effective Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice
This study aimed to determine whether the multi-kinase inhibitor dasatinib would provide an effective therapy for myeloproliferative diseases (MPDs) involving c-Cbl mutations. These mutations, which occur in the RING finger and linker domains, abolish the ability of c-Cbl to function as an E3 ubiqui...
Autores principales: | Duyvestyn, Johanna M., Taylor, Samuel J., Dagger, Samantha A., Orandle, Marlene, Morse, Herbert C., Thien, Christine B. F., Langdon, Wallace Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981816/ https://www.ncbi.nlm.nih.gov/pubmed/24718698 http://dx.doi.org/10.1371/journal.pone.0094717 |
Ejemplares similares
-
Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders
por: Naramura, Mayumi, et al.
Publicado: (2011) -
Ubiquitin Ligases CBL and CBL-B Maintain the Homeostasis and Immune Quiescence of Dendritic Cells
por: Tong, Haijun, et al.
Publicado: (2021) -
VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease
por: An, Wei, et al.
Publicado: (2016) -
Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases
por: Tang, Rong, et al.
Publicado: (2022) -
Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)